Cargando…
Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies
Drug-induced myopathies are classified as acquired myopathies caused by exogenous factors. These pathological conditions develop in patients without muscle disease and are triggered by a variety of medicaments, including lipid-lowering drugs (LLDs) such as statins, fibrates, and ezetimibe. Here we s...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198905/ https://www.ncbi.nlm.nih.gov/pubmed/34073503 http://dx.doi.org/10.3390/ijms22115654 |
_version_ | 1783707250235277312 |
---|---|
author | Dubińska-Magiera, Magda Migocka-Patrzałek, Marta Lewandowski, Damian Daczewska, Małgorzata Jagla, Krzysztof |
author_facet | Dubińska-Magiera, Magda Migocka-Patrzałek, Marta Lewandowski, Damian Daczewska, Małgorzata Jagla, Krzysztof |
author_sort | Dubińska-Magiera, Magda |
collection | PubMed |
description | Drug-induced myopathies are classified as acquired myopathies caused by exogenous factors. These pathological conditions develop in patients without muscle disease and are triggered by a variety of medicaments, including lipid-lowering drugs (LLDs) such as statins, fibrates, and ezetimibe. Here we summarise the current knowledge gained via studies conducted using various models, such as cell lines and mammalian models, and compare them with the results obtained in zebrafish (Danio rerio) studies. Zebrafish have proven to be an excellent research tool for studying dyslipidaemias as a model of these pathological conditions. This system enables in-vivo characterization of drug and gene candidates to further the understanding of disease aetiology and develop new therapeutic strategies. Our review also considers important environmental issues arising from the indiscriminate use of LLDs worldwide. The widespread use and importance of drugs such as statins and fibrates justify the need for the meticulous study of their mechanism of action and the side effects they cause. |
format | Online Article Text |
id | pubmed-8198905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-81989052021-06-14 Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies Dubińska-Magiera, Magda Migocka-Patrzałek, Marta Lewandowski, Damian Daczewska, Małgorzata Jagla, Krzysztof Int J Mol Sci Review Drug-induced myopathies are classified as acquired myopathies caused by exogenous factors. These pathological conditions develop in patients without muscle disease and are triggered by a variety of medicaments, including lipid-lowering drugs (LLDs) such as statins, fibrates, and ezetimibe. Here we summarise the current knowledge gained via studies conducted using various models, such as cell lines and mammalian models, and compare them with the results obtained in zebrafish (Danio rerio) studies. Zebrafish have proven to be an excellent research tool for studying dyslipidaemias as a model of these pathological conditions. This system enables in-vivo characterization of drug and gene candidates to further the understanding of disease aetiology and develop new therapeutic strategies. Our review also considers important environmental issues arising from the indiscriminate use of LLDs worldwide. The widespread use and importance of drugs such as statins and fibrates justify the need for the meticulous study of their mechanism of action and the side effects they cause. MDPI 2021-05-26 /pmc/articles/PMC8198905/ /pubmed/34073503 http://dx.doi.org/10.3390/ijms22115654 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Dubińska-Magiera, Magda Migocka-Patrzałek, Marta Lewandowski, Damian Daczewska, Małgorzata Jagla, Krzysztof Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies |
title | Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies |
title_full | Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies |
title_fullStr | Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies |
title_full_unstemmed | Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies |
title_short | Zebrafish as a Model for the Study of Lipid-Lowering Drug-Induced Myopathies |
title_sort | zebrafish as a model for the study of lipid-lowering drug-induced myopathies |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8198905/ https://www.ncbi.nlm.nih.gov/pubmed/34073503 http://dx.doi.org/10.3390/ijms22115654 |
work_keys_str_mv | AT dubinskamagieramagda zebrafishasamodelforthestudyoflipidloweringdruginducedmyopathies AT migockapatrzałekmarta zebrafishasamodelforthestudyoflipidloweringdruginducedmyopathies AT lewandowskidamian zebrafishasamodelforthestudyoflipidloweringdruginducedmyopathies AT daczewskamałgorzata zebrafishasamodelforthestudyoflipidloweringdruginducedmyopathies AT jaglakrzysztof zebrafishasamodelforthestudyoflipidloweringdruginducedmyopathies |